Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26263273 | 0.88 | ALDH1A1 (0.54) | EGLN1CTSLHPGDS | |
| SCHEMBL26264447 | 0.87 | KAT6A (0.51) | KAT6AADCY8ADCY1HDAC8HPGDS | |
| SCHEMBL31445988 | 0.86 | CTSL (0.57) | GPR132EGLN1CTSL | |
| SCHEMBL26263274 | 0.85 | ALDH1A1 (0.64) | KAT6AGPR132CTSL | |
| SCHEMBL26263281 | 0.83 | SUCNR1 (0.52) | GPR132CTSL | |
| SCHEMBL31446720 | 0.83 | ALDH1A1 (0.58) | EGLN1CTSL | |
| SCHEMBL1427713 | 0.78 | ALDH1A1 (0.58) | GPR132CTSL | |
| SCHEMBL265506 | 0.78 | ALDH1A1 (0.58) | GPR132CTSL | |
| SCHEMBL2853466 | 0.78 | ALDH1A1 (0.58) | GPR132CTSL | |
| SCHEMBL26263203 | 0.78 | GPR132 (0.52) | GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | KAT6A 2977/4885GPR132 433/4885EGLN1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.